Driven by rapid clinical translation, industrial-scale allogeneic production, and sustained public–private investment, the ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...
QuantumScape released its Q3 2024 business report this afternoon, and the biggest news is an update regarding the progress of its solid-state battery development and production. According to the ...
The agency outlined the adjustments it's willing to make to "remove barriers and perceived misconceptions" for innovative medicines.
Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.
HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. ("Pluri”, the "Company”, "we” or "us”) (Nasdaq, TASE: PLUR), a leading biotechnology company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback